89zr-lncab103
Gastric Cancer (GC)
Affiliated Hospital of Jiangnan UniversityradiopharmaceuticalEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
282 Active assets in the Gastric Cancer (GC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 | BBB |
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 4 | BB |
Eloxatin Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
Epirubicin Rondo Therapeutics | Phase 3 | BB |
View all 50 →
Same molecule, other indications
89zr-lncab103 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →